Recursive partitioning as an approach to selection of immune markers for tumor diagnosis.
OBJECTIVE
Cancer sera contain antibodies which react with a unique group of autologous cellular antigens called tumor-associated antigens (TAAs), but the low frequency of positive reactions against any individual antigen has precluded use of autoantibodies as useful diagnostic markers. With enzyme immunoassay, we examined antibody frequencies to a panel of seven TAAs, c-myc, cyclin B1, IMP1, Koc, p53, p62, and survivin, in 527 cancer patients (64 breast cancer patients, 45 colorectal cancers, 91 gastric cancers, 65 hepatocellular carcinomas, 56 lung cancers, and 206 prostate cancers), and 346 normals. We used recursive partitioning to assess whether we could accurately classify individuals as either cancer patients or normals on the basis of the profile of antibody reactivity to the seven TAAs for each individual.


RESULTS
Recursive partitioning resulted in the selection of subsets of the seven-panel TAA, which differentiated between tumors and controls, and these subsets were unique to each cancer cohort. The classification trees had sensitivities ranging from 0.77 to 0.92 and specificities ranging from 0.85 to 0.91 in the cancer cohorts when normal means +2 SDs were used as standard cutoffs for immunoassay positivity. Antibody to cyclin B1 was the initial discriminating node for gastric and lung cancers, and for hepatocellular carcinoma, and was a subsequent discriminating node in all of the other cancer cohorts. c-myc was the initial discriminating node in breast cancer, p62 in prostate cancer, and IMP1 in colon cancer. Recursive partitioning demonstrated that no more than three of the seven TAAs were needed for any cancer cohort to arrive at these levels of sensitivity and specificity.


CONCLUSIONS
This initial study shows that multiple antigen miniarrays can provide accurate and valuable tools for cancer detection and diagnosis. Performance of the miniarrays might be enhanced by other combinations of TAAs appropriately selected for different cancer cohorts.
Koziol
James A
JA
Division of Biomathematics, The Scripps Research Institute, La Jolla, California 92037, USA.
Zhang
Jian-Ying
JY
Casiano
Carlos A
CA
Peng
Xuan-Xian
XX
Shi
Fu-Dong
FD
Feng
Anne C
AC
Chan
Edward K L
EK
Tan
Eng M
EM
D000912:Antibodies, Neoplasm / Q000032:analysis*; D001323:Autoantibodies / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis*; D016022:Case-Control Studies; D015331:Cohort Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D009369:Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology; D012680:Sensitivity and Specificity; D014481:United States / Q000453:epidemiology
D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D014408:Biomarkers, Tumor